期刊
JOURNAL OF CLINICAL HYPERTENSION
卷 20, 期 1, 页码 39-44出版社
WILEY
DOI: 10.1111/jch.13140
关键词
ambulatory blood pressure; antihypertensive treatment; home blood pressure; morning blood pressure; morning hypertension
资金
- Bayer
- Boehringer-Ingelheim
- Daiichi-Sankyo
- MSD
- Novartis
- Omron
- Pfizer
- Sanofi
- Servier
- Fukuda Denshi
- Omron Healthcare
- Bayer Yakuhin
- MSD K.K.
- Mochida Pharmaceutical
- Novartis Pharma K.K.
- Sumitomo Dainippon Pharma
- Boehringer Ingelheim Japan
- Daiichi Sankyo
- Takeda Pharmaceutical
- Astellas Pharma
- Teijin Pharma
- Bristol-Myers K.K
- Shionogi
Morning blood pressure (BP) surge is an important aspect of hypertension research. Morning BP monitoring could be a clinically relevant concept in the therapeutic management of hypertension and in the prevention of cardiovascular complications by defining and treating morning hypertension. Because antihypertensive medication is often taken in the morning, uncontrolled morning BP during the trough effect hours could be a hallmark of inadequate choice of antihypertensive regimen, such as the use of short- or intermediate-acting drugs, underdosing of drugs, or no use or underuse of combination therapy. To improve the management of hypertension in general and morning hypertension in particular, long-acting antihypertensive drugs should be used in appropriate, often full dosages and in proper combinations. The clinical usefulness of antihypertensive drugs with specific mechanisms for morning BP or split or timed dosing of long-acting drugs in controlling morning BP remains under investigation.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据